What’s an SGLT-2 inhibitor and how does it work? Includes cool FAQ!
Diabetes Drug News
Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.
Metformin Insulin SGLT-2 GLP-1 DPP-4 Combo drugs Sulfonylureas TZDs
57 readers recommended
In June, pharmaceutical giant Bristol-Myers Squibb (BMS) and its partner AstraZeneca (AZ) acquired the important biotech company Amylin for a cool $7 billion, which we...
47 readers recommended
On November 8, an FDA advisory panel voted 8-4 to recommend approval of Novo Nordisk’s ultra-long-acting basal insulin degludec (to be marketed under the name “Tresiba...
57 readers recommended
Can a drug for type 2 diabetes work for those with type 1? How will a new basal insulin compare to Lantus?
36 readers recommended
Dr. Arya Sharma highlights the most important weight loss tip everyone should know and why weight maintenance is a major achievement.
56 readers recommended
The past few months have seen the approval of a pair of new drugs designed to treat obesity, Arena’s Belviq (see new now next in diaTribe #44) and Vivus’ Qsymia (see new...
26 readers recommended
How can the FDA change its view on drug approvals to give patients access to better therapies?
30 readers recommended
Many people with diabetes fear eye diseases leading to blindness. In diabetic macular edema (DME), the leading cause of blindness among working-age Americans (over 560,...
50 readers recommended
In late November, Vivus launched its Get Started! Program , which gives potential users of its weight management medication Qsymia a chance to try the drug free for two...
37 readers recommended
On February 8, Novo Nordisk received an FDA complete response letter (CRL) for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/aspart). Tresiba is Novo Nordisk’...
72 readers recommended
By Hannah Deming Lately, the use of basal insulins (such as Lantus and Levemir) in combination with GLP-1 agonists (such as Byetta , Victoza , and Bydureon ) has been...
31 readers recommended
In December, Novo Nordisk announced that it will advance FIAsp, an ultra-rapid-acting version of Novolog (insulin aspart), directly into phase 3 trials in late 2013 (the...
54 readers recommended
In January, the FDA announced the approval of three of Takeda’s new once-daily DPP-4 inhibitor pills for type 2 diabetes. DPP-4 inhibitors have been the best-selling...
42 readers recommended
As noted in new now next in diaTribe #37, Novo Nordisk announced in October 2011 that it had submitted its two new “next-generation” insulin products for approval in the...
31 readers recommended
On November 28, CeQur announced that it had received CE Mark approval for its PaQ Insulin Delivery Device , allowing the product to be sold in Europe. The Swiss-based...
51 readers recommended
On February 1, the European Commission announced that it had approved Sanofi and Zealand Pharma’s GLP-1 agonist Lyxumia (lixisenatide) for type 2 diabetes. The drug is a...
36 readers recommended
A candid interview with diaTribe advisory board member Dr. Anne Peters touches on the newest drugs and devices, curing type 1, and addressing obesity.
43 readers recommended
This month, in a surprise move, Vivus announced that its weight management medication Qsymia is now available via mail order through Walmart. This is an addition to the...
76 readers recommended
A study in the Journal of the American Medical Association ( JAMA ) found that patients with type 2 diabetes who had been taking the GLP-1 agonists Bydureon (exenatide...
24 readers recommended
Two well-known endocrinologists debated the merits of inhaled insulin in the February edition of Diabetes Care.